CLDX
Celldex Therapeutics Inc
31.10$
-1.2%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -15.6% | -18.1% | +149.6% | +2.5% | -11.9% | +17.7% | -32.1% | -65.9% | +87.5% | -19.2% | -49.8% | -23.6% | +62.5% | +207.6% | -91.3% | +183.1% | +466.6% | -81.9% | +408.0% | -95.6% | +118.3% | -47.9% | -6.3% | +149.7% | +296.3% | -40.0% | -72.3% | +466.0% | +172.3% | -96.2% | +1,501.3% | +27.7% | -63.2% | -40.9% | +5.0% | -100.0% | – | -80.0% | +46.7% | – | |
| – | -100.0% | +2,579,200.0% | -3.1% | -12.3% | +7.1% | -6.8% | -2.0% | -44.4% | -14.4% | +9.2% | -9.6% | +10.1% | -6.9% | +13.1% | -17.0% | +10.3% | -2.6% | +22.0% | -2.9% | +9.7% | +8.3% | +16.2% | +21.5% | +4.1% | +6.2% | +17.0% | -2.0% | -97.1% | +3,866.9% | -97.5% | +2.8% | +5,579.2% | -98.2% | +6,324.2% | +3.0% | +16.1% | – | – | – | – | |
| – | – | -1,395.2% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -3,606.0% | – | – | -2,573.4% | – | -14,684.0% | – | – | – | -1,218.7% | – | – | |
| – | -1.8% | +5.0% | -3.1% | -12.3% | +7.1% | -6.8% | -2.0% | -44.4% | -6.0% | -0.5% | -9.6% | +10.1% | -6.9% | +13.1% | +12.9% | -18.9% | +165.5% | -55.3% | -2.9% | +38.0% | -13.9% | +16.2% | +21.5% | +4.1% | +6.2% | +17.0% | -2.0% | +31.6% | -11.9% | +1.5% | +25.9% | +16.4% | +1.9% | +14.1% | +3.0% | +16.1% | +19.7% | -3.1% | -7.5% | – | |
| – | +71.7% | -39.4% | -9.6% | -18.2% | +10.3% | -5.1% | +0.5% | -33.8% | +16.4% | +13.0% | -20.2% | -12.9% | -5.4% | +13.9% | -3.8% | +3.2% | -0.5% | +13.7% | +4.5% | +35.2% | +7.2% | +10.7% | +3.5% | -8.7% | +1.0% | +0.6% | +8.7% | +13.8% | +7.4% | +3.1% | +0.3% | +10.1% | +2.1% | +5.4% | -4.0% | +2.8% | +11.4% | -3.8% | +14.4% | – | |
| – | +409.8% | -70.4% | -28.5% | +80.1% | -60.5% | +2,142.6% | -101.5% | – | – | +123.2% | -64.8% | -55.4% | +174.4% | +10.3% | -51.4% | +126.9% | +321.7% | -74.6% | -0.9% | +62.6% | -19.2% | +6.3% | +148.3% | -58.7% | +1.0% | +0.6% | +8.8% | +481.5% | -49.2% | +87.5% | +20.1% | -79.1% | +460.8% | -80.8% | -4.0% | +2.8% | +716.6% | -4.2% | -3.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | -60.0% | +2,874.5% | -100.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | -93.4% | +7.8% | +89.4% | +132.7% | +53.3% | +122.5% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -75.0% | -507.5% | – | – | – | – | – | – | -157.1% | – | – | – | – | – | -186.3% | – | -50.0% | -159.4% | – | – | – | -105.5% | – | – | – | – | – | -94.5% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.